Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ribociclib - Novartis Oncology

Next Previous
Drug Profile

Ribociclib - Novartis Oncology

Alternative Names: Kisqali; LEE-011; LEE-011A

Latest Information Update: 11 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics; Mount Sinai Health System
  • Developer Array BioPharma; Cedars-Sinai Medical Center; Cincinnati Children's Hospital Medical Center; Cliniques Universitaires Saint Luc; Dana-Farber Cancer Institute; Georgetown University; Gynecologic Oncology Group; Hadassah Medical Organization; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Taiwan University Hospital; Novartis; Novartis Oncology; Roswell Park Cancer Institute; Seagen; SOLTI Breast Cancer Research Group; St Josephs Hospital and Medical Center; Thomas Jefferson University; UNICANCER; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center; Virginia Mason Research Center
  • Class Amides; Aminopyridines; Antineoplastics; Piperazines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Oligodendrocyte transcription factor 2 inhibitors; Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Cancer; Malignant melanoma; Neuroendocrine tumours; Ovarian cancer; Peritoneal cancer
  • Phase I/II Liposarcoma; Neuroblastoma; Pancreatic cancer; Triple negative breast cancer
  • Phase I Glioma; Medulloblastoma; Rhabdoid tumour; Rhabdomyosarcoma
  • No development reported Lymphoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
  • Discontinued Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Liver cancer; Meningioma; Prostate cancer; Teratoma

Most Recent Events

  • 10 Apr 2024 Phase-III clinical trials in Breast cancer (Combination therapy, Adjuvant therapy, Early-stage disease) in Australia (PO) (NCT05827081)
  • 21 Mar 2024 Updated efficacy data from the phase III NATALEE trial in Breast Cancer released by Novartis
  • 27 Feb 2024 Preregistration for Breast cancer (Second-line therapy or greater, Adjuvant therapy) in USA (PO) (Novartis pipeline, February 2024).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top